Premium
The Bruton’s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody‐mediated T‐cell cytotoxicity
Author(s) -
Godwin Colin D.,
Bates Olivia M.,
Garling Eliotte E.,
Beddoe Mary E.,
Laszlo George S.,
Walter Roland B.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16406
Subject(s) - ibrutinib , bruton's tyrosine kinase , blinatumomab , cancer research , chronic lymphocytic leukemia , tyrosine kinase , t cell , cd19 , cytotoxicity , chimeric antigen receptor , chemistry , pharmacology , antigen , medicine , immunology , leukemia , in vitro , immune system , receptor , biochemistry